ArticleJournal of immunotherapy and precision oncology2026

Response to RAF/MEK/ERK Inhibitors in Patients with RAS-Altered and Wild-Type Tumors.

Mohamed A Gouda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.